Closed · RFA-HD-09-025 · CFDA 93.865 · Discretionary
Noninvasive Assays of Human Oocytes and Preimplantation Embryos (SBIR [R43])
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- up to $100K
- Award range
- Closed
- Status
- November 10, 2009
- Close date
- -
- Expected awards
The verdict
Noninvasive Assays of Human Oocytes and Preimplantation Embryos (SBIR [R43]) is a closed discretionary listing from National Institutes of Health that offered Up to $100,000. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.
- up to $100K
- award range
- Closed
- application status
- 93.865
- CFDA program
- 12,419
- other opportunities from National Institutes of Health
Archived opportunity record
Noninvasive Assays of Human Oocytes and Preim… is closed (last close November 10, 2009). Check the agency catalog for replacement NOFOs. National Institutes of Health still indexes 12,419 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed November 10, 2009
Est. Total Funding
$300,000
Instrument
Grant
Description
Purpose. This Funding Opportunity Announcement (FOA) solicits Small Business Innovative Research (SBIR) grant applications from small business concerns (SBCs) that propose to establish high resolution, non-invasive assays of single human oocytes and preimplantation embryos that will serve to evaluate the quality and developmental potential of oocytes or embryos produced by in vitro fertilization laboratories. The assays must have certain features such as rapidity, low expense, simple laboratory manipulations and a high level of accuracy. A major goal of this initiative is to encourage and increase the use of single embryo transfers for assisted reproduction. This would reduce health risks to the mother and the offspring that result from multiple pregnancies, thereby reducing the high medical costs associated with these adverse outcomes. Mechanism of Support. This FOA will utilize the SBIR (R43) grant mechanism for Phase I applications and runs in parallel with a FOA of identical scientific scope, RFA-HD-09-024, which solicits applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms.
Small-business / for-profit corridor · RFA-HD-09-025
Noninvasive Assays of Human Oocytes and Preim… prints a for-profit / small-business applicant door (Small businesses). Treat the listing as business-facing unless the full Grants.gov announcement narrows it further. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity codes span Health · Income Security and Social Services (HL;ISS). 789 other National Institutes of Health listings share this eligibility-code string (6% of 12,420).
- Code 23
- Small businesses
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
What to do next
Noninvasive Assays of Human Oocytes and Preim… is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 93.865 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |